Shibao Feng

Title: Shibao Feng: Innovator in Cancer Treatment

Introduction

Shibao Feng is a prominent inventor based in Zürich, Switzerland. He has made significant contributions to the field of oncology, particularly in the treatment of B-cell lymphomas. His innovative approach combines targeted therapies to improve patient outcomes.

Latest Patents

Shibao Feng holds a patent for a method of treating indolent or aggressive B-cell lymphomas. The patent, which is titled "Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors," describes a method for preventing, delaying progression, or treating these lymphomas. The method involves administering a BTK inhibitor, specifically (S)-7-(1-acetyloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetrahydropyrazolo-[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an anti-PD-1 antibody. This combination has shown a manageable toxicity profile in patients suffering from indolent and aggressive lymphomas. Shibao Feng has 1 patent to his name.

Career Highlights

Shibao Feng is currently associated with Beigene Switzerland GmbH, where he continues to work on innovative cancer therapies. His research focuses on developing effective treatments that enhance the quality of life for patients with challenging lymphomas.

Collaborations

Shibao Feng collaborates with notable colleagues, including James Hilger and Xiaoping Zhang. Their combined expertise contributes to advancing research in cancer treatment.

Conclusion

Shibao Feng is a dedicated inventor whose work in the treatment of B-cell lymphomas showcases the potential of innovative therapies in oncology. His contributions are paving the way for improved patient care and outcomes in the fight against cancer.